MNG720
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.478
- INTERFERON_ALPHA_RESPONSE+0.463
- INTERFERON_GAMMA_RESPONSE+0.412
- TNFA_SIGNALING_VIA_NFKB+0.381
- ALLOGRAFT_REJECTION+0.350
- MYC_TARGETS_V2+0.339
- P53_PATHWAY+0.338
- UV_RESPONSE_UP+0.299
- WNT_BETA_CATENIN_SIGNALING+0.292
- INFLAMMATORY_RESPONSE+0.283
Top 10 suppressed
- PROTEIN_SECRETION-0.488
- MYC_TARGETS_V1-0.345
- MTORC1_SIGNALING-0.337
- ANDROGEN_RESPONSE-0.301
- G2M_CHECKPOINT-0.258
- GLYCOLYSIS-0.233
- E2F_TARGETS-0.217
- OXIDATIVE_PHOSPHORYLATION-0.200
- ANGIOGENESIS-0.165
- PANCREAS_BETA_CELLS-0.161
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG399 | — | — | 0.804 |
| 2 | BS_893A91ZM | Neurofibroma | — | 0.781 |
| 3 | R60 | — | — | 0.771 |
| 4 | BS_3Y0QXZQB | Neurofibroma | — | 0.770 |
| 5 | R83 | — | — | 0.767 |
| 6 | 63229_S123 | — | cohortA1 | 0.763 |
| 7 | BS_HZRM07TW | Med | Medulloblastoma | 0.747 |
| 8 | TCGA-AR-A1AK-01A-21R-A12P-07 | — | A | 0.744 |
| 9 | BS_2W3NC4K1 | Neurofibroma | — | 0.740 |
| 10 | MNG708 | — | — | 0.739 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.478 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.463 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.412 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.381 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.339 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.338 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.299 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.292 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.283 | Idelalisib | — uncovered |
| APOPTOSIS | 0.262 | Idelalisib | — uncovered |
| MYOGENESIS | 0.205 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.205 | Inavolisib | — uncovered |
| COAGULATION | 0.201 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.176 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.171 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.156 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.144 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.124 | Inavolisib | — uncovered |
| COMPLEMENT | 0.116 | Inavolisib | — uncovered |